Protagenic Therapeutics Warrant
PTIXW
PTIXW was delisted on the 2nd of January, 2026.
6 hedge funds and large institutions have $2.63K invested in Protagenic Therapeutics Warrant in 2025 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 1 closing their positions.
78% more capital invested
Capital invested by funds: $1.48K → $2.63K (+$1.15K)
1.37% more ownership
Funds ownership: 6.3% → 7.67% (+1.4%)
0% more funds holding
Funds holding: 6 → 6 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Clear Street
New York
|
+$510 |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$13 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$87 |
| 2 |
TSS
Two Sigma Securities
New York
|
-$61 |
| 3 |
HF
HRT Financial
New York
|
-$11 |
| 4 |
GS
GTS Securities
New York
|
-$1 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
WAM
1
Warberg Asset Management
Winnetka,
Illinois
| $1.28K | – | – | – |
|
|
CS
2
Clear Street
New York
| $750 | +$510 | +100,000 | New |
|
|
3
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $376 | -$87 | -16,989 | -25% |
|
|
GS
4
GTS Securities
New York
| $202 | -$1 | -100 | -0.4% |
|
|
5
UBS Group
Zurich,
Switzerland
| $21 | +$13 | +2,640 | +733% |
|
|
TSS
6
Two Sigma Securities
New York
| – | -$61 | -17,500 | Closed |
|
|
HF
7
HRT Financial
New York
| – | -$11 | -2,150 | -10% |
|
PTIXW Hedge Fund Activity: Q1 2025 in Review
6 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Protagenic Therapeutics Warrant (PTIXW) for Q1 2025, worth a combined $2.63K — up 78% from $1.48K a quarter earlier.
Fund positioning in PTIXW was balanced in Q1 2025: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 3 trimmed.
The largest buyer was Clear Street, opening a new position worth an estimated $510. The largest seller was Susquehanna International Group, cutting an estimated $87.
- 6 institutional investors held Protagenic Therapeutics Warrant (PTIXW) as of Q1 2025, unchanged from Q4 2024.
- Funds reported $2.63K of Protagenic Therapeutics Warrant stock for Q1 2025, up 78% quarter-over-quarter.
- 1 fund opened new Protagenic Therapeutics Warrant positions in Q1 2025 and 1 closed out, a net change of 0 holders.
- The largest Protagenic Therapeutics Warrant buyer in Q1 2025 was Clear Street, an estimated $510 added.
- The largest Protagenic Therapeutics Warrant seller in Q1 2025 was Susquehanna International Group, an estimated $87 sold.
Based on aggregated 13F filings for Q1 2025.